The Food and Drug Administration said it would delay the
implementation of a new rule on off-label drug promotion that
was scheduled to take effect on Tuesday for a year after
receiving a petition from drug industry groups that say the rule
impermissibly expands the agency's authority.
In a notice published in the Federal Register on Friday, the
FDA said it was delaying the rule until March 19, 2018 so it
could consider public comments. Such comments must be received
by May 19, the agency said.
To read the full story on WestlawNext Practitioner Insights,
click here: bit.ly/2nLwnUl